If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials

J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210. doi: 10.1200/JCO.2009.24.5456. Epub 2009 Oct 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology
  • Antibiotics, Antineoplastic / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Cell Line, Tumor / drug effects
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Female
  • Humans
  • Metformin / pharmacology
  • Metformin / therapeutic use*
  • Protein Kinases / drug effects
  • Protein Kinases / metabolism
  • Receptor, IGF Type 1 / metabolism*
  • Risk Assessment
  • Sensitivity and Specificity
  • Signal Transduction
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases

Substances

  • Antibiotics, Antineoplastic
  • Metformin
  • Protein Kinases
  • MTOR protein, human
  • Receptor, IGF Type 1
  • TOR Serine-Threonine Kinases
  • Sirolimus